Inqovi (Decitabine/Cedazuridine) Patent Expiration, LOE Window & CMS Spending
Inqovi (Decitabine/Cedazuridine) by Taiho Oncology: FDA Orange Book core substance LOE 2034-02-12 (last listed 2042-12-10), 0 AB generics, $96.4M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Taiho Oncology |
| FDA Application & Pathway | N212576 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-02-12 |
| Last Listed Patent or Exclusivity Date | 2042-12-10 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $96.4M |
| 2024 Medicare Part D Spend | $94.5M |
| 2024 Medicaid Spend | $1.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |